Introduction {#Sec1}
============

Ataxia is a term used to describe unsteadiness and poor co-ordination of movements. It can occur secondary to cerebellar dysfunction (cerebellar ataxia) or because of dysfunction within the peripheral or central sensory pathways (sensory ataxia).

Cerebellar ataxia can be inherited (e.g. Friedreich's ataxia and spinocerenellar ataxias, known as SCAs) or acquired (e.g. gluten ataxia and paraneoplastic) \[[@CR1]\].

Sensory ataxia is commonly seen in neuropathies that involve sensory fibers and are more prominent in pure sensory neuropathies involving the dorsal root ganglia, commonly referred to as sensory ganglionopathies (SG) \[[@CR2]\]. Causes of SG can be inherited (e.g. mitochondrial disorders) or acquired (e.g. paraneoplastic) \[[@CR3]--[@CR5]\].

Cerebellar ataxia combined with SG is a relatively rare neurological combination, which can sometimes be seen in the context of hereditary ataxias \[[@CR2]\] (e.g. Friedreich's ataxia and SCA4, mitochondrial disease and Cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS) \[[@CR6]\]) or as a result of exposure to toxins (e.g. amiodarone \[[@CR7]\]).

We present a case series of patients with this unusual combination, in an attempt to shed light into possible underlying aetiology.

Methods {#Sec2}
=======

Standard protocol approvals, registrations, and patient consents {#Sec3}
----------------------------------------------------------------

This is a retrospective observational case series of patients regularly attending the Ataxia clinic based at the Royal Hallamshire Hospital (Sheffield, UK). The South Yorkshire Research Ethics Committee has confirmed that no ethical approval is indicated given that all investigations were clinically indicated and did not form part of a research study.

Patient selection {#Sec4}
-----------------

All recruited patients had clinical and neuroimaging evidence of progressive cerebellar dysfunction as well as clinical and neurophysiological evidence of SG.

Neurophysiological assessments {#Sec5}
------------------------------

All patients underwent detailed nerve conduction studies including median (sensory and motor), ulnar (sensory and motor), superficial radial (sensory), sural (sensory), superficial peroneal (sensory) and tibial (motor). All sensory nerve conduction studies were performed bilaterally. On all occasions supramaximal stimulation of the nerves was performed.

The diagnosis of SG was based on the established diagnostic criteria \[[@CR8], [@CR9]\]. Clinically patients that presented with signs and symptoms of patchy sensory symptoms and reduced or absent tendon reflexes underwent nerve conduction studies. SG was confirmed electrophysiologically with complete absence of sensory nerve action potentials (SNAPs) or asymmetrical sensory fiber involvement (asymmetrical SNAPs) with no motor involvement.

Neuroimaging assessments {#Sec6}
------------------------

All patients underwent a magnetic resonance imaging (MRI) of the brain and a magnetic resonance spectroscopy (MRS) of the cerebellum. The latter technique is validated and is used to determine the presence of cerebellar dysfunction, even in the absence of cerebellar atrophy \[[@CR10]\]. We measured the N-acetyl-aspartate/creatine (NAA/Cr) ratios in the vermis and the cerebellar hemispheres. Only patients with cerebellar atrophy and/or abnormal NAA/Cr ratios in either the vermis or the hemispheres and/or cerebellar atrophy in the MRI where considered as having cerebellar dysfunction.

Serologic testing {#Sec7}
-----------------

Serological testing was performed and included extensive testing for possible acquired causes of cerebellar ataxia and sensory ganglionopathy. Human leukocyte antigen (HLA) typing was performed by the regional blood-transfusion service.

Genetic testing {#Sec8}
---------------

Patients with early onset cerebellar ataxia and/or family history of ataxia were tested genetically for possible genetic causes. A muscle biopsy was done in patients with a suspected mitochondrial disease. By default we did not include in this case series patients with Friedreich's ataxia (FA) as this is a well known cause of this combination of neurological deficits.

Enteropathy {#Sec9}
-----------

Patients with gluten sensitivity underwent gastroscopy and duodenal biopsy to establish the presence of enteropathy. All biopsies were histologically assessed for evidence of enteropathy (triad of villous atrophy, crypt hyperplasia, and increase in intraepithelial lymphocytes).

Statistical analysis {#Sec10}
--------------------

A database was developed using the statistical software package SPSS (version 23.0 for Macintosh). Descriptive statistics were examined for each variable.

Results {#Sec11}
=======

Clinical characteristics {#Sec12}
------------------------

We identified 40 patients (45% males) with combined cerebellar ataxia and sensory ganglionopathy. Mean age at onset of the symptoms was 53.7 ± 14.7 years (range 8--80) and mean age at first presentation was 56.6 ± 13.5 years (range 14--81). At presentation, the majority of patients (40%) were diagnosed with cerebellar ataxia and 30% were diagnosed with SG. For 30% the two diagnoses were made at the same time. The mean latency between the two diagnoses was 6.5 ± 8.9 years (range 0--44). The commonest initial manifestation was unsteadiness (77.5%) followed by patchy sensory loss (17.5%) and peripheral neuropathic pain (5%).

Neurophysiology {#Sec13}
---------------

Sixteen patients (40%) had absent SNAPs, whereas the rest had asymmetrical SNAPs. No patients had abnormal compound muscle action potentials (CMAPs). Table [1](#Tab1){ref-type="table"} summarizes the neurophysiological characteristics of a typical patient with asymmetrical SNAPs (Patient 1) and of a patient with completely absent SNAPs (Patient 2) from these series.Table 1Neurophysiological characteristics of a typical patient with asymmetrical SNAPs (Patient 1) and of a patient with completely absent SNAPs (Patient 2) from these seriesSubjectNCS\
ParameterMedian\
CMAPUlnar (ADM)\
CMAPTibial\
CMAPMedian\
SNAPUlnar\
SNAPRadial\
SNAPSural\
SNAPSuperficial Peroneal\
SNAPSide(R)(R)(R)(R)(L)(R)(L)(R)(L)(R)(L)(R)(L)Patient 1\
(Asymmetric SNAPs)\
46Y, FemaleAmplitude14.1 mV10.7 mV9.2 mV17.4 μV6.1 μV3.1 μV5.7 μV18.4 μV12.4 μV21.5 μV12.8 μV7.7 μV3.4. μVConduction velocity60 m/s\
(Elbow-Wrist)60 m/s\
(Below elbow -- Wrist)\
70 m/s\
(Above elbow -- below elbow)NC56 m/s\
(Digit III --Wrist)60 m/s\
(Digit III --Wrist)58 m/s\
(Digit V --Wrist)57 m/s\
(Digit V--Wrist)58 m/s\
(Forearm- Snuff Box55 m/s\
Forearm- Snuff Box48 m/s\
Calf -- lateral malleolus48 m/s\
Calf -- lateral malleolus48 m/s\
Leg -- Dorsum of the foot47 m/s\
Leg -- Dorsum of the footPatient 2\
(Absent SNAPS)\
67Y, MaleAmplitude8.3 mV6.3 mV3.0 mVNRNRNRNRNRNRNRNRNRNRConduction velocity54 m/s\
(Elbow-Wrist)48 m/s\
(Below elbow -- Wrist)\
59 m/s\
(Above elbow -- below elbow)NCNANANANANANANANANANA*NCS* nerve conduction studies, *CMAP* compound muscle action potential, *SNAP* sensory nerve action potential, *ADM* abductor digiti minimi, *R* right, *L* left, *NC* not checked, *NR* not recordable, *NA* not applicable

Neuroimaging characteristics {#Sec14}
----------------------------

All patients had abnormal MRS at diagnosis. Fifteen patients (37.5%) had low NAA/Cr ratio only in the vermis (\<0.96) and 6 patients (15%) had low NAA/Cr ratio only in the hemispheres (\<1). Nineteen patients (47.5%) had low NAA/Cr ratio in both the vermis and the hemispheres. Only 55% of the patients had cerebellar atrophy in the initial MRI.

Evidence of autoimmunity {#Sec15}
------------------------

Nineteen patients (47.5%) had gluten sensitivity, of whom 3 patients (7.5%) had biopsy proven coeliac disease. Other abnormal immunological tests were present in another 15 patients (i.e. GAD, ANA etc.), of whom 4 patients (10%) had biopsy proven Sjogren's syndrome.

Cancer {#Sec16}
------

Nine patients had a history or developed malignancy (3 bowel, 1 melanoma, 1 light chain myeloma, 2 ovarian, 1 uterus and 1 of unknown primary location). However, only in 6 patients of them the malignancy was diagnosed within 5 years of the neurological symptoms. Anti-Yo antibodies were found in one patient.

Genetic causes {#Sec17}
--------------

Nineteen patients were investigated for familial ataxias using next generation sequencing ataxia panel containing 42 genes. In selected patients genetic testing for common mitochondrial mutations (including POLG1) and muscle biopsies were performed. For two of them a genetic cause was identified (one mitochondrial, one SCA18).

HLA type {#Sec18}
--------

HLA typing was performed in 34 patients. Of them, 18 patients (52.9%) had the DQ2 type, 6 patients (17.6%) had the DQ8 type, 9 patients (26.5%) had the DQ1 type and 1 patient (2.9%) had another HLA type.

Truly idiopathic cases {#Sec19}
----------------------

After extensive immunological and genetic screening, only 3 patients (7.5%) were classified as having a truly idiopathic combination of cerebellar ataxia with SG (Table [2](#Tab2){ref-type="table"}).Table 2Clinical, neuroimaging and serological characteristics of all patientsGenderAge at 1st presentationFirst symptomsAge at first symptomsFirst diagnosisSecond symptomsAge at second diagnosisMRIAbnormal\
MRSSNAPsGluten serologyDuodenum biopsyHLAOther evidence of autoimmunityCancerAge at cancer diagnosisGeneticsTruly idiopathicFemale48Unsteadiness in the dark48SGWorsening of balance63Normal for ageVermis and hemisphereAbsentNegativeN/ADQ2ENA+ ANA+, Crohn'sNegativeFemale59Patchy numbness57SGNo new symptoms60Normal for ageVermisAsymmetricalPositiveCDDQ2TPO+, dsDNA+, RF+Ovarian38Male40Patchy numbness38SGWorsening of balance62Normal for ageVermisAbsentPositiveNormalDQ2P-ANCA+, ANA+, GM1+, SarcoidosisMale60Patchy burning pain59SGNo new symptoms65Normal for ageHemisphereAsymmetricalPositiveNormalDQ2Female76Unsteadiness/Numbness76SGWorsening of balance84Normal for ageHemisphereAsymmetricalPositiveCDDQ2Male49Patchy numbness49SGNo new symptoms72Normal for ageHemisphereAbsentNegativeN/ADQ1ANA+, RF+NegativeMale52Pain in feet49SGWorsening of balance70Normal for ageVermisAsymmetricalNegativeN/ADQ1ANA+, P-ANCA+, SACE+Female55Patchy numbness55SGWorsening of balance69Normal for ageVermisAsymmetricalNegativeN/ANot doneANA+, ENA+ (Sjogren's)Male67Unsteadiness64SGWorsening of balance68Cerebellar atrophyVermisAbsentNegativeN/ADQ2ANA+, P-ANCA+, MGUSFemale61Patchy pain61SGWorsening of balance67Normal for ageHemisphereAsymmetricalNegativeN/ANot doneANA+, ENA+ (Sjogren's)Female58Patchy numbness57SGWorsening of balance74Normal for ageHemisphereAsymmetricalNegativeN/AOtherYesFemale35Patchy numbness35SGWorsening of balance49Normal for ageVermis and hemisphereAsymmetricalNegativeN/ANot doneANA+, ENA+ (Sjogren's)Female42Unsteadiness42Cerebellar ataxiaPatchy sensory loss46Cerebellar atrophyVermis and hemisphereAsymmetricalNegativeN/ADQ1Anti-Yo+Ovarian41Male14Unsteadiness14Cerebellar ataxiaWorsening of balance58Cerebellar atrophyVermisAsymmetricalPositiveCDDQ2GAD+MitochondrialFemale57Unsteadiness/Dizziness55Cerebellar ataxiaSensory symptoms69Cerebellar atrophyVermisAbsentPositiveNormalDQ1GAD+SCA18Male52Unsteadiness51Cerebellar ataxiaSensory symptoms57Cerebellar atrophyVermis and hemisphereAbsentPositiveNormalDQ8NegativeFemale50Unsteadiness/\
Slurred speech47Cerebellar ataxiaSensory symptoms54Cerebellar atrophyVermis and hemisphereAsymmetricalPositiveNot doneDQ2RF+NegativeMale44Unsteadiness39Cerebellar ataxiaNo new symptoms46Cerebellar atrophyVermisAsymmetricalPositiveNormalDQ8NegativeFemale54Unsteadiness53Cerebellar ataxiaSensory symptoms60Cerebellar atrophyVermis and hemisphereAsymmetricaPositiveNormalDQ2Colon69NegativeMale67Unsteadiness54Cerebellar ataxiaNo new symptoms76Cerebellar atrophyVermis and hemisphereAbsentPositiveNormalDQ2ANA+NegativeMale66Unsteadiness66Cerebellar ataxiaNo new symptoms67Cerebellar atrophyVermis and hemisphereAbsentNegativeN/ADQ2ANA+Bowel68Female66Unsteadiness63Cerebellar ataxiaSensory symptoms68Normal for ageVermis and hemisphereAbsentNegativeN/ADQ2NegativeYesFemale65Unsteadiness59Cerebellar ataxiaPatch sensory loss68Cerebellar atrophyVermisAbsentNegativeN/ADQ8C-ANCA+, MGUSMyltiple myeloma - light chain70NegativeFemale46Unsteadiness46Cerebellar ataxiaPatchy sensory loss58Cerebellar atrophyVermisAsymmetricalNegativeN/ADQ1TPO+NegativeFemale66Unsteadiness64Cerebellar ataxiaNo new symptoms69Normal for ageVermis and hemisphereAsymmetricalNegativeN/ADQ2NegativeYesFemale68Unsteadiness67Cerebellar ataxiaSensory symptoms69Normal for ageVermis and hemisphereAbsentNegativeN/ADQ2ANA+, TPO+Male81Unsteadiness79Cerebellar ataxiaWorsening of balance85Normal for ageVermis and hemisphereAsymmetricalNegativeN/ANot doneMGUSMelanoma/\
Possibly prostate86Female29Unsteadiness8Cerebellar ataxiaSensory symptoms33Cerebellar atrophyVermis and hemisphereAsymmetricalPositiveNormalDQ2OCB+, TPO+, GAD+ (one occasion only)NegativeMale43Unsteadiness34Both at the same time43Cerebellar atrophyHemisphereAsymmetricalPositiveNormalDQ2RF+Female61Unsteadiness/Numbness60Both at the same time61Cerebellar atrophyVermisAbsentPositiveNormalDQ1Malignancy of unknown primary location64NegativeFemale81Unsteadiness80Both at the same time81Cerebellar atrophyVermisAsymmetricalPositiveNormalNot doneMale51Unsteadiness/Numbness51Both at the same time51Cerebellar atrophyVermis and hemisphereAsymmetricalPositiveNormalDQ1Female55Unsteadiness/Pain49Both at the same time55Cerebellar atrophyVermisAbsentNegativeN/ADQ1GAD+, P-ANCA+Uterus39NegativeMale64Unsteadiness54Both at the same time64Cerebellar atrophyVermis and hemisphereAbsentNegativeN/ADQ8MGUSNegativeMale70Unsteadiness67Both at the same time70Normal for ageVermisAbsentNegativeN/ADQ1C-ANCA+Male54Unsteadiness49Both at the same time54Cerebellar atrophyVermis and hemisphereAsymmetricalNegativeN/ADQ2TPO+Female70Unsteadiness69Both at the same time70Normal for ageVermis and hemisphereAsymmetricalNegativeN/ANot doneANA+, ENA+ (Sjogren's), RF+Bowel71Male57Unsteadiness55Both at the same time57Cerebellar atrophyVermisAbsentPositiveNormalDQ2NegativeMale61Unsteadiness/Numbness61Both at the same time62Normal for ageVermis and hemisphereAsymmetricalPositiveNormalDQ8ENA+Female69Unsteadiness64Both at the same time69Cerebellar atrophyVermis and hemisphereAsymmetricalPositiveNormalDQ8P-ANCA+

Discussion {#Sec20}
==========

Our case series highlights that amongst patients with cerebellar ataxia and sensory neuronopathy, where a genetic or a malignant cause is not identified, immune pathogenesis is a likely cause. In fact out of 40 patients, only 2 were found to have a genetic cause and only 6 patients had malignancy, which was diagnosed within 5 years of their symptoms. From the remaining 32 patients the vast majority (91%) had evidence of autoimmunity and only 3 patients (9%) were classified as truly idiopathic.

Whether considering the cut-off of 5 years for a neurological syndrome to be classified as paraneoplastic is a matter of debate \[[@CR11]\]. This time period has been based on reports showing that in the majority of cases the interval between the paraneoplastic neurological syndrome and the diagnosis of malignancy is less than 5 years \[[@CR11]\]. However in our case series, there are patients who exceed this interval. The type of malignancy, however, may influence this interval.

The HLA type has been linked to predisposition to autoimmunity. In our case series 70.5% of patients had the DQ2 or the DQ8 HLA subtypes, which are known to be associated with autoimmunity. This percentage is significantly higher compared to the 40% of the general population \[[@CR12]\]. In addition, in our cohort, evidence for autoimmunity (serological evidence of gluten sensitivity and/or positive other antibody titers) was present in 90% of the patients.

Our findings should be interpreted with some caution given the limitations of our design. Firstly, as this is a retrospective observational case series of patients regularly attending our Ataxia clinic not all patient's had full genetic screening, which means that the percentage of genetic causes might be higher than the one we reported. However, the bias is probably minimized by the fact that we genetically tested patients with early onset and/or family history of ataxia and SG. When clinically suspected, patients also underwent genetic testing for mitochondrial diseases including muscle biopsies. Despite this it is possible that in some patients mitochondrial aetiology \[[@CR13], [@CR14]\] may have been missed. Secondly, we haven't routinely been examining for the vestibulo-ocular reflex and therefore cases of CANVAS may have been missed. However, our understanding is that most cases with CANVAS, unlike the series here, tend to have a family history.

Both cerebellar ataxia (gluten ataxia) and sensory ganglionopathy in isolation have been previously linked to gluten sensitivity \[[@CR4], [@CR10], [@CR15]\]. Almost half of the patients in this report (47.5%) had serological evidence of gluten sensitivity without enteropathy (coeliac disease). Gluten free diet has already been shown to be beneficial in such patients \[[@CR4]\] and should be considered in all patients with cerebellar ataxia and sensory ganglionopathy in the presence of serological markers of sensitivity to gluten.
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